Effects of osteoporosis medications on bone quality

Joint Bone Spine

Volumn 74, Issue 1, 2007, Pages 39-47

  Benhamou, Claude Laurent ^a  

^a CENTRE HOSPITALIER RÉGIONAL D ORLÉANS   (France)

Author keywords

Bisphosphonates; Bone quality; Microarchitecture; Osteoporosis; PTH; Selective estrogen receptor modulator (SERM); Strontium ranelate

Indexed keywords

ALENDRONIC ACID; CALCITONIN; ETIDRONIC ACID; INCADRONIC ACID; NERIDRONIC ACID; PARATHYROID HORMONE[1-34]; PLACEBO; RALOXIFENE; RISEDRONIC ACID; STRONTIUM RANELATE;

BONE ATROPHY; BONE BIOPSY; BONE DENSITY; BONE MINERAL; BONE MINERALIZATION; BONE NECROSIS; BONE STRENGTH; BONE TURNOVER; DRUG EFFECT; DRUG EFFICACY; DUAL ENERGY X RAY ABSORPTIOMETRY; HUMAN; INFRARED SPECTROSCOPY; MORPHOMETRICS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOGENESIS IMPERFECTA; OSTEOLYSIS; OSTEOPOROSIS; PATIENT MONITORING; POSTMENOPAUSE OSTEOPOROSIS; RADIATION SCATTERING; SHORT SURVEY; THERAPY EFFECT; THREE DIMENSIONAL IMAGING; TREATMENT RESPONSE; VERTEBRA DISLOCATION;

AGED; AGED, 80 AND OVER; ANIMALS; BIOLOGICAL MARKERS; BONE AND BONES; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE RESORPTION; DIPHOSPHONATES; FEMALE; FRACTURES, SPONTANEOUS; HUMANS; MALE; MIDDLE AGED; OSTEOGENESIS; OSTEOPOROSIS; RISK ASSESSMENT; TERIPARATIDE;

EID: 33846951516     PISSN: 1297319X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbspin.2006.06.004     Document Type: Short Survey

References (70)

1. Marshall D., Johnell O., and Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 312 (1996) 1254-1259
2. Melton L.J., Kan S.H., Frye M.A., Wahner H.W., O'Fallon W.M., and Riggs B.L. Epidemiology of vertebral fractures in women. Am J Epidemiol 129 (1989) 1000-1011
3. Kanis J.A., Johansson H., Oden A., Johnell O., de Lact C., Melton III L.J., et al. A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res 19 (2004) 893-899
4. Szulc P., Beck T.J., Marchand F., and Delmas P.D. Low skeletal muscle mass is associated with poor structural parameters of bone and impaired balance in elderly men. The Minos Study. J Bone Miner Res 20 (2005) 721-729
5. Consensus Development conference. Prophylaxis and treatment of osteoporosis. Am J Med 94 (1993) 646-650
6. NIH Consensus Development Panel in osteoporosis prevention, diagnosis, and therapy. JAMA 285 (2001) 785-795
7. e édition (2005), Doin Editeur, Paris
8. C.L. Benhamou, coord. Les déterminants multi échelle de la fragilité osseuse-Comité d'Interface Inserm-Appareil (2005), Laboratoires Servier Editeur
9. Chesnut III C.H., and Rosen C.J. Reconsidering the effects of antiresorptive therapies in reducing osteoporotic fracture. J Bone Miner Res 16 (2001) 2163-2172
10. Bone Quality. What is it and can we measure it? NIH and ASBMR Meeting (May 2005), ASBMR
11. Kanis J.A., Johnell O., Oden A., de Laet C., Jonsson B., and Dawson A. Ten-year risk of osteoporotic fracture and the effect of risk factors on screening strategies. Bone 30 (2002) 251-259
12. Sarkar S., Mitlab B., Wong M., Stock J.L., Black D.M., and Harper K.D. Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. J Bone Miner Res 17 (2002) 1-10
13. Meunier P., Roux C., Seeman E., Ortolani S., Badurski J., Spector T., et al. Effects of strontium ranelate on vertebral fracture risk in postmenopausal women. N Engl J Med 350 (2004) 459-468
14. Reginster J.Y., Seeman E., de Vernejoul M.C., Adami S., Compston J., Phenekos C., et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis. J Clin Endrocrinol Metab 90 (2005) 2816-2822
15. Watts N.B., Cooper C., Lindsay R., Eastell R., Manhart M., Barton I.P., et al. Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate. J Clin Densitom 7 (2004) 256-261
16. Cummings S.R., Karpf D.B., Harris F., Genant H.K., Ensrud K., Lacroix A.Z., et al. Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med 112 (2002) 281-289
17. Li Z., Meredith M.P., and Hoseyni M.S. A method to assess the proportion of treatment effect explained by surrogate endpoint. Stat Med 20 (2001) 3175-3188
18. Hochberg M., Greenspan S., Wasnich R., Miller P., Thomson D., and Ross P. Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab 87 (2002) 1586-1592
19. Roux C., Seeman E., Eastell R., Adachi J., Jackson R., Felsenberg D., et al. Efficacy of risedronate on clinical vertebral fractures within six months. Curr Med Res Opin 20 (2004) 433-439
20. Maricic M., Adachi J.D., Sarkar S., Wu W., Wong M., and Harper K.D. Early effects of raloxifene on clinical vertebral fractures at 12 months in post-menopausal women with osteoporosis. Arch Intern Med 162 (2002) 1140-1143
21. Weinstein R.S. True strength. J Bone Miner Res 15 (2000) 621-627
22. Eastell R., Barton I., Hannon R.A., Chines A., Garnero P., and Delmas P.D. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 18 (2003) 051-056
23. Cummings S.R. How drugs decrease fracture risk: lessons from trials. J Musculoskel Neuron Interact 2 (2002) 198-200
24. Ott S. Long-term safety of bisphosphonates. J Clin Endocrinol Metab 90 (2005) 1897-1899
25. Bauer D., Black D., Garnero P., Hochberg M., Ott S., Orloff J., et al., for the fracture intervention trial study group. Changes in bone turnover and hip, non-spine and vertebral fracture in alendronate-treated women: the fracture intervention trial. J Bone Miner Res 19 (2004) 1250-1258
26. Bjarnason N.H., Sarkar S., Duong T., Mitlak B., Delmas P.D., and Christiansen C. Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis. Osteoporosis Int 12 (2001) 922-930
27. Neer R.M., Arnaud C.D., Zanchetta J.R., Prince R., Gaich G.A., Reginster J.Y., et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344 (2001) 1434-1441
28. Orwoll E.S., Scheele W.H., Paul S., Adami S., Syversen U., Diez-Perez A., et al. The effect of teriparatide [Human Parathyroid Hormone (1-34)]. J Bone Miner Res 18 (2003) 9-17
29. Zanchetta J., Bogado C., Ferretti J., Wang O., and Wilson M.G. Sato M et al. Effects of teriparatide [recombinant human parathyroid hormone (1-34)] on cortical bone in postmenopausal women with osteoporosis. J Bone Miner Res 18 (2003) 539-543
30. Rehman Q., Lang T.F., Arnaud C.D., Modin G.W., and Lane N.E. Daily treatment with parathyroid hormone is associated with an increase in vertebral cross-sectional area in postmenopausal women with glucocorticoid-induced osteoporosis. Osteoporosis Int 14 (2003) 77-81
31. Lindsay R., Scheele W.H., Neer R., Pohl G., Adami S., Carlos M., et al. Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis. Arch Intern Med 164 (2004) 2024-2030
32. Rittmaster R.S., Bolognese M., Ettinger M., Hanley D.A., Hodsman A.B., Kendler D.L., et al. Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. J Clin Endocrinol Metab 85 (2000) 2129-2134
33. Prince R., Sipos A., Hossain A., Syversen U., Ish-Shalom S., Marcinowska E., et al. Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment. J Bone Miner Res 20 (2005) 1507-1513
34. Gatti D., Viapiana O., Lippolis I., Braga V., Prizzi R., Rossini M., et al. Intravenous bisphosphonate therapy increases radial width in adults with osteogenesis imperfecta. J Bone Miner Res 20 (2005) 1323-1326
35. Greenspan S.L., Beck T.J., Resnick N.M., Bhattacharya R., and Parker R.A. Effect of hormone replacement alendronate, or combination therapy on hip structural geometry: a 3-year, double-blind, placebo-controlled clinical trial. J. Bone Miner Res 20 (2005) 1525-1532
36. Tommasini S.M., Nasser P., Schaffler M.B., and Jepsen K.J. Relationship between bone morphology and bone quality in male tibias. J Bone Miner. Res 20 (2005) 1372-1380
37. Jiang Y., Zhao J.J., Mitlak B.H., Wang O., Genant H.K., and Eriksen E.F. Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure. J Bone Miner Res 18 (2003) 1932-1941
38. Benhamou C.L., Chappard C., Gadois C., Lemineur G., Lespessailles E., de Vernejoul M.C., et al. Characterization of trabecular micro-architecture improvement under teriparatide by a fractal analysis of texture on calcaneus radiographs. J Bone Miner Res 1 Suppl (2004) S126
39. Benhamou C.L., Lespessailles E., Jacquet G., Harba R., Jennane R., Loussot T., et al. Fractal organization of trabecular bone images on calcaneus radiographs. J Bone Miner Res 9 (1994) 1909-1918
40. Pothuaud L., Benhamou C.L., Porion P., Lespessailles E., Harba R., Levitz P., et al. Fractal dimension of trabecular bone projection texture is related to three-dimensional microarchitecture. J Bone Miner Res 15 (2000) 691-699
41. Borah B., Dufresne T.E., Chmielewski P.A., Gross G.J., Prenger M.C., and Phipps R.J. Risedronate preserves trabecular architecture and increases bone strength in vertebra of ovariectomized minipigs as measured by 3-D computed tomography. J Bone Miner Res 17 (2002) 1139-1147
42. Dufresne T.E., Chmielewski P.A., Mannhart M.D., Johnson T.D., and Borah B. Risedronate preserves bone architecture in early postmenopausal women in 1 year as measured by 3-D microcomputed tomography. Calcif Tissue Int 73 (2003) 423-432
43. Borah B., Dufresne T.E., Chmielewski P.A., Johnson T.D., Chines A., and Mannhart M.D. Risedronate preserves bone architecture in postmenopausal women with osteoporosis as measured by 3-D micro computed tomography. Bone 34 (2004) 736-746
44. Recker R., Masarachia P., Santora A., Howard T., Chavassieux P., and Arlot M. Trabecular bone microarchitecture after alendronate treatment of osteoporotic women. Curr Med Res Opin 21 (2005) 185-194
45. Benhamou C.L., Basillais A., Aufort G., Chappard C., Jennane R., Masarachia P., et al. Application of a three dimensional skeleton graph analysis to patients treated by alendronate on placebo on micro-computed tomography images. NIAMS-ASBMR Scientific Meeting-Bone Quality: What is it and can we measure it? May 2-3, 2005, Bethesda, MD, USA. p. 34-36.
46. Chesnut III C.H., Majumdar S., Newitt D.C., Shields A., Van Pelt J., Laschansky E., et al. Effects of salmon calcitonin on trabecular microarchitecture as determined by MRI: results from the QUEST study. J Bone Miner Res 20 (2005) 1548-1561
47. Lespessailles E., Poupon S., Niamane R., Loiseau-Pérès S., Derommelaere G., Harba R., et al. Fractal analysis of trabecular bone texture on calcaneus radiographs: effects of age, time since menopause and hormonal replacement therapy on microarchitectural changes. Osteoporosis Int 13 (2002) 366-372
48. Boivin G., and Meunier P.J. The degree of mineralization of bone tissue measured by computerized quantitative contact microradiography. Calcif Tissue Int 70 (2000) 503-511
49. Boivin G., and Meunier P.J. Methodological considerations in measurement of bone mineral content. Osteoporosis Int 5 Suppl (2003) 22-28
50. Turner C.H. Biomechanics of bone: determinants of skeletal fragility and bone quality. Osteoporosis Int 13 (2002) 97-104
51. Boivin G., Chavassieux P.M., Santora A.C., Yates J., and Meunier P.J. Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone 27 (2000) 687-694
52. Boivin G., Arlot M., Trechsel U., and Meunier P.J. Effects of intravenous zoledronic acid on the degree of mineralization of bone in post-menopausal osteoporosis: a quantitative microradiographic analysis of transiliac biopsies after one year. J Bone Miner Res 2 Suppl (2003) S261
53. Boivin G., Vedi S., Purdie D.W., Compston J.E., and Meunier P.J. Influence of estrogen therapy at conventional and high doses on the degree of mineralization of iliac bone tissue: a quantitative microradiographic analysis in postmenopausal women. Bone 36 (2005) 562-567
54. Boivin G., Lips P., Ott S.M., Harper K.B., Sarkar S., Pinette V., et al. Contribution of raloxifene and calcium and vitamin D. Supplementation to the increase of the degree of mineralization of bone in postmenopausal women. J Clin Endocrinol Metab 88 (2003) 4199-4205
55. Nuzzo S., Peyrin F., Cloetens P., Bachurel J., and Boivin G. Quantification of the degree of mineralization of bone in three dimension using synchrotron radiation microtomography. Med Phys 29 (2002) 2672-2681
56. Borah B., Ritman E., Dufresne T., Jorgensen S., Liu S., Sacha J., et al. The effect of risedronate on bone mineralization as measured by micro-CT with synchrotron radiation: correlation to histomorphometric indices of turnover. Bone 37 (2005) 1-9
57. Misof B.M., Roschger P., Cosman F., Kurland E.S., Tesch W., Messmer P., et al. Effects of intermittent parathyroid hormone administration on bone mineralization density in iliac crest biopsies from patients with osteoporosis: a paired study before and after treatment. J Clin Endocrinol Metab 88 (2003) 1150-1156
58. Paschalis E.P., Betts F., Dicarlo E., Mendelson R., and Boskey A.L. FTIR Microspectroscopic analysis of normal human cortical and trabecular bone. Calcif Tissue Int 61 (1997) 480-486
59. Paschalis EP, Phipps R. Long-term treatment with risedronate preserves bone quality. International Conference on Progress in Bone and Mineral Research, Vienna, November 27; 2003.
60. Burr D. Microdamage and bone strength. Osteoporosis Int 5 Suppl (2003) S67-S72
61. Hirano T., Turner C.H., Forwood H., Johnston C., and Burr D. Does suppression of bone turnover impair mechanical properties by allowing microdamage accumulation?. Bone 27 (2000) 13-20
62. Burr D., Miller L., Grynpas M., Li J., Boyde A., Mashiba T., et al. Tissue mineralization is increased following 1-year treatment with high doses of bisphosphonates in dogs. Bone 33 (2003) 960-969
63. Komatsubara S., Mori S., Mashiba T., Li J., Nonaka K., Kaji Y., et al. Suppressed bone turnover by long-term bisphosphonate treatment accumulates microdamage but maintains intrinsic material properties in cortical bone of dog rib. J Bone Miner Res 19 (2004) 999-1005
64. Mashiba T., Turner C.H., Hirano T., Forwood M.R., Johnston C.C., and Burr D.B. Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. Bone 28 (2001) 524-531
65. Allen M.R., Iwata K., Phipps R., and Burr D. Risedronate and alendronate similarly suppress remodelling and increase microdamage in beagles after 1 year of treatment at clinical doses. J Bone Miner Res 1081 (2005) S22
66. Martin R.B. Fatigue microdamage as an essential element of bone mechanics and biology. Calcif Tissue Int 73 (2003) 101-107
67. Ruggiero S., Mebrotra B., Rosenberg T., and Engroff S. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 62 (2004) 527-534
68. Durie B.G. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 353 (2005) 99-102
69. Bamias A., Kastritis E., Bamia C., Moulopoulos L.A., Melakopoulos I., Bozas G., et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 23 (2005) 8580-8587
70. Afssaps. Lettre aux prescripteurs. Information de pharmacovigilance. Acide zolédronique/pamidronate de sodium et ostéonécrose de la mâchoire. 24 juin 2005.